AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 141 min read$INBX

Lappe Mark purchased $849K of INBX (indirect holdings)

Lappe Mark (Chief Executive Officer) purchased 10,040 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $84.56 ($84.07–$85.76, $0.85M total) across 6 trades on 2026-10-14.

Original reporting
SEC EDGAR · Lappe Mark
Published Oct 14, 2026, 10:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 11:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INBX
Bullish
medium confidence
Mentioned
$INBX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INBXBullishLow
01

Why it matters

The CEO's purchase modestly raises his ownership, which can be interpreted as a positive signal but is unlikely to move the stock significantly on its own.

02

Market read

The filing provides a fresh insider buying event, offering a modest bullish cue for traders monitoring INBX.

03

What to watch

Potential upcoming clinical data or financing events not disclosed in the filing could be driving the insider's confidence.

Relevance 6/10Novelty 4/10Timing: after-hours on 2026-10-14

Background

Form 4 filings disclose insider transactions and are primary sources for such activity.

Company-level read

Ticker impact

$INBXBullishMedium confidence
Context

CEO Mark Lappe purchased 10,040 shares for $848,977, raising his stake to 170,000 shares.

Expected impact

likely upward pressure as the market prices in the insider purchase.

Evidence & confidence

The purchase is modest in absolute dollars but represents a significant stake increase by the CEO, which can be viewed as a bullish signal.

Market effects

Sector

Minimal; the biotech sector may note the insider confidence but no broader impact.

Regional

None; the filing is company‑specific.

Global

Low; limited to investors tracking INBX.

Counterpoint

What could challenge this read

The purchase is small relative to market cap and may be routine compensation, not a strong bullish cue.

Key entities

  • company
    Inhibrx Biosciences, Inc.

    Biotech firm focused on developing therapies for rare diseases.

  • person
    Mark Lappe

    Chief Executive Officer of INBX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INBX insider trading history →

Related articles

SEP 8
$INBXMedAI 8/10

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx Biosciences (INBX) reported positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs 26.5% for pembrolizumab alone, with 9.6-month median PFS. HPV+ patients saw even stronger results. The company plans to expand the trial and explore further applications. INBRX-106 is a hexavalent OX40 agonist.

prnewswire.com2 min
SEP 8
$INBXHighAI 8/10

Inhibrx stock jumps on positive cancer drug trial results

Inhibrx Biosciences (NASDAQ:INBX) shares rose 6% after reporting positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs. 26.5% for pembrolizumab alone. The study included 63 patients, with notable improvements in HPV-positive patients. The company plans to expand the trial and align with the FDA for a potential accelerated pathway.

investing.com2 min
AUG 13
$INBXMedAI 8/10

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.

prnewswire.com4 min
AUG 13
$INBXMed

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program

SEC EDGAR 8-K6 min